Back to Search
Start Over
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study
- Source :
- Oncology. 94
- Publication Year :
- 2018
-
Abstract
- Objectives: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced breast cancer (BC) in a real-life setting. Methods: This retrospective monocentric study included patients with HER-2-negative metastatic BC, pretreated with anthracyclines and taxanes, who were referred to the Oncology Department of Spedali Civili of Brescia from May 2012 to April 2017. Patients received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m2 on days 1 and 8 every 21 days. Results: In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival (PFS) was 4.7 months and median overall survival (OS) 13.53 months. Median PFS was significantly longer in patients who reported a CB compared to those with no CB, while survival outcomes (PFS and OS) were better in patients who received > 6 cycles of eribulin. Eribulin showed a good tolerability profile with acceptable toxicities, similar to those reported in EMBRACE. Conclusions: Our experience in a real-world setting confirms the activity, efficacy, and good tolerability profile of eribulin in heavily pretreated BC patients.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
Receptor, ErbB-2
chemistry.chemical_compound
ErbB-2
0302 clinical medicine
Stable Disease
Eribulin
Metastatic breast cancer
Overall survival
Progression-free survival
Real-world practice
Safety
Adult
Aged
Anthracyclines
Antineoplastic Agents
Breast Neoplasms
Disease-Free Survival
Female
Furans
Humans
Ketones
Middle Aged
Retrospective Studies
Taxoids
Treatment Outcome
General Medicine
Tolerability
030220 oncology & carcinogenesis
Receptor
medicine.medical_specialty
03 medical and health sciences
Internal medicine
medicine
business.industry
Cancer
Retrospective cohort study
medicine.disease
030104 developmental biology
chemistry
Clinical Study
business
Subjects
Details
- ISSN :
- 14230232
- Volume :
- 94
- Database :
- OpenAIRE
- Journal :
- Oncology
- Accession number :
- edsair.doi.dedup.....bee5335b2d4d0dd104e97ebccbfd1781